# WEST PHARMACEUTICAL SERVICES, INC. (WST) · Edgar & Edgarette company card > West Pharmaceutical Services (WST) grew revenue 6.3% in FY2025 to $3.1 billion, operating margin 19.0% against a 1.2% median for surgical & medical instruments & apparatus, equity 74.4% of assets, and dividend per share up 14 years running. Every figure is from the company’s own annual report filed with the SEC. SEC CIK 105770 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/WST) · [JSON](https://www.pops4.com/boards/company/WST.json) ## Figures, as filed in the 10-K | Measure | Value | |---|---| | Revenue | $3.1B | | Revenue growth, 1 year | 6.3% | | Revenue growth per year | 2.1% | | Operating margin | 19.0% (prior year 19.7%) | | Net margin | 16.1% | | Operating cash flow | $755M | | Capital spending | $286M | | Free cash flow | $469M | | Cash | $791M | | Long-term debt | $203M | | Total assets | $4.3B | | Total equity | $3.2B | | Equity ÷ assets | 74.4% | | Return on equity | 15.5% | | Dividend per share | $0.86 | | Dividend years rising | 14 | ## Readings, computed from those figures - Altman Z: 9.34 (safe zone) - Piotroski F: 7 of 9 (solid) - Beneish M: -2.79 (below the −1.78 line) - Health Harbor boat: Sound ship · one warning sign · filed cybersecurity incident in the last 12 months - Cash Compass: Cash cow now · steady, with strong cash arriving today ## Edgarette's reading Exposure: revenue $3.1B (FY2025), total debt $202.8M. Experience: revenue up 6.3% on the year, up 2.1% a year over 4 years; operating margin 19.0%, down from 19.7%. Soundness: equity 74.4% of assets, return on equity 15.5%, payout 12.4% of profit, dividend per share up 14 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.9B and $3.4B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.7B to $3.7B. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 19.0% against a 1.2% median; growth 6.3% against 11.6%. Range logged 2026-10-27, receipt 29fe83850ff901fa, status open. A statistical range, not company guidance. ## Health Watch, last 12 months - Item 1.05 Cybersecurity incident: 1, latest 2026-05-11 ([filing](https://www.sec.gov/Archives/edgar/data/105770/000010577026000068/0000105770-26-000068-index.htm)) - Item 5.02 Director or officer change: 2, latest 2026-06-01 ([filing](https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm)) ## Recent filings - 8-K · filed 2026-10-26 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/105770/000010577026000114/0000105770-26-000114-index.htm) - 10-Q · filed 2026-07-23 · [filing](https://www.sec.gov/Archives/edgar/data/105770/000010577026000099/0000105770-26-000099-index.htm) - 8-K · filed 2026-07-23 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/0000105770-26-000097-index.htm) - 8-K · filed 2026-07-14 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/105770/000010577026000093/0000105770-26-000093-index.htm) - 8-K · filed 2026-06-01 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm) - 8-K · filed 2026-05-11 · 1.05 Material Cybersecurity Incidents; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/105770/000010577026000068/0000105770-26-000068-index.htm) ## Sources - facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000105770.json - filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=105770 ## Cite POPS4, Edgar & Edgarette: WEST PHARMACEUTICAL SERVICES, INC. (WST) company card, from the company's own SEC filings, accessed 2026-10-27, https://www.pops4.com/boards/company/WST. CC BY 4.0. For a figure, add the filing URL under filings or sources. DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4. Reporting, not investment advice. No price targets and no trading recommendations. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.